Combined therapy with gaba and proinsulin/alum acts synergistically to restore long-term normoglycemia by modulating t-cell autoimmunity and promoting b-cell replication in newly diabetic nod mice

Diabetes

Volumn 63, Issue 9, 2014, Pages 3128-3134

  Tian, Jide ^a   Dang, Hoa ^a   Nguyen, An Viet ^a   Chen, Zheying ^a   Kaufman, Daniel L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALUMINUM POTASSIUM SULFATE; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 4; PROINSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL DIVISION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; HELPER CELL; HUMORAL IMMUNITY; INSULITIS; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REMISSION; T LYMPHOCYTE;

ALUM COMPOUNDS; ANIMALS; AUTOIMMUNITY; BLOOD GLUCOSE; CELL DIVISION; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; INTERLEUKIN-10; INTERLEUKIN-4; MICE; MICE, INBRED NOD; PROINSULIN; T-LYMPHOCYTES, REGULATORY;

EID: 84906661994     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1385     Document Type: Article

References (24)

1. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M; ITNJDRF Type 1 Diabetes Combination Therapy Assessment Group. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 2010;160:176-184
2. Peakman M, von Herrath M. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes 2010;59:2087-2093
3. Staeva TP, Chatenoud L, Insel R, Atkinson MA. Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes 2013;62:9-17
4. Tian J, Kaufman DL. Antigen-based therapy for the treatment of type 1 diabetes. Diabetes 2009;58:1939-1946
5. Tian J, Clare-Salzler M, Herschenfeld A, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996;2:1348-1353
6. Pop SM, Wong CP, He Q, et al. The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes 2007;56:1395-1402
7. Tian J, Chau C, Hales TG, Kaufman DL. GABA(A) receptors mediate inhibition of T cell responses. J Neuroimmunol 1999;96:21-28
8. Alam S, Laughton DL, Walding A, Wolstenholme AJ. Human peripheral blood mononuclear cells express GABAA receptor subunits. Mol Immunol 2006; 43:1432-1442
9. Mendu SK, Bhandage A, Jin Z, Birnir B. Different subtypes of GABA-A receptors are expressed in human, mouse and rat T lymphocytes. PLoS One 2012;7:e42959
10. Tian J, Lu Y, Zhang H, Chau CH, Dang HN, Kaufman DL. Gammaaminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. J Immunol 2004;173: 5298-5304
11. Tian J, Yong J, Dang H, Kaufman DL. Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. Autoimmunity 2011;44:465-470
12. Bhat R, Axtell R, Mitra A, et al. Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci U S A 2010;107:2580-2585
13. Soltani N, Qiu H, Aleksic M, et al. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc Natl Acad Sci U S A 2011; 108:11692-11697
14. Mendu SK, Akesson L, Jin Z, et al. Increased GABA(A) channel subunits expression in CD8(+) but not in CD4(+) T cells in BB rats developing diabetes compared to their congenic littermates. Mol Immunol 2011;48:399-407
15. Prud'homme GJ, Glinka Y, Hasilo C, Paraskevas S, Li X, Wang Q. GABA protects human islet cells against the deleterious effects of immunosuppressive drugs and exerts immunoinhibitory effects alone. Transplantation 2013;96:616-623
16. Tian J, Dang H, Yong J, Chui W-S, Dizon M, Yaw CKY, Kaufman DL. Oral treatment with g-Aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice. PLoS One 2011;6: e25338
17. Tian J, Dang H, Kaufman DL. Combining antigen-based therapy with GABA treatment synergistically prolongs survival of transplanted b-cells in diabetic NOD mice. PLoS One 2011;6:e25337
18. Ligon B, Yang J, Morin SB, Ruberti MF, Steer ML. Regulation of pancreatic islet cell survival and replication by gamma-Aminobutyric acid. Diabetologia 2007;50:764-773
19. Tian J, Dang H, Chen Z, et al. γ-Aminobutyric acid regulates both the survival and replication of human ß-cells. Diabetes 2013;62:3760-3765
20. Otomo E, Araki G, Mori A, Kurihara M. Clinical evaluation of GABA in the treatment of cerebrovascular disorders. Multi-center double-blind study in comparison with pyrithioxine and placebo. Arzneimittelforschung 1981;31:1511-1523
21. Loeb C, Benassi E, Bo GP, Cocito L, Maffini M, Scotto P. Preliminary evaluation of the effect of GABA and phosphatidylserine in epileptic patients. Epilepsy Res 1987;1:209-212
22. Tower DB, Roberts E. Inhibition in the Nervous System and GABA. New York, Pergamon Press, 1960, p. 562-578
23. Tian J, Gregori S, Adorini L, Kaufman DL. The frequency of high avidity T cells determines the hierarchy of determinant spreading. J Immunol 2001;166: 7144-7150
24. Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993;366:69-72